BRAF mutation in papillary thyroid carcinoma.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of the National Cancer Institute

• Publication date

  2003-04-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/JNCI/95.8.625PMID 12697856
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002influential reference
• Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status

  2002cited by this paper
• Discovery of a novel Raf kinase inhibitor.

  2001cited by this paper
• Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade.

  2001cited by this paper
• Thyroid cancer.

  2001cited by this paper
• Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.

  2001cited by this paper
• p44/p42-MAP kinase expression in papillary thyroid carcinomas.

  2001cited by this paper
• The Raf/MEK/ERK pathway: new concepts of activation

  2001cited by this paper
• The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway

  2000cited by this paper
• MEK Wars, a new front in the battle against cancer

  1999cited by this paper
• PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.

  1990cited by this paper

• The critical role of ferroptosis in thyroid cancer development and potential therapeutic implications

  2026cites this paper
• Highly sensitive profiling somatic mutations of thyroid cancer by nucleotide-enrichment-based MALDI-TOF MS assay

  2026influential citation
• Progress in Drug-targeted Therapy for Papillary Thyroid Carcinoma

  2025cites this paper
• Targeted RNA sequencing of thyroid tumors from individuals with PTEN hamartoma tumor syndrome reveals a unique transcriptome with a predominantly RAS-like expression profile.

  2025cites this paper
• DriverSub-SVM: a machine learning approach for cancer subtype classification by integrating patient-specific and global driver genes

  2025cites this paper
• Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies

  2025cites this paper
• Prognostic value of BRAF V600E mutation in papillary thyroid carcinoma: a meta-analysis of nodal involvement, distant metastases, recurrence, and mortality.

  2025cites this paper
• Molecular Biomarkers in Borderline Ovarian Tumors: Towards Personalized Treatment and Prognostic Assessment

  2025cites this paper
• BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity

  2025cites this paper
• Significance and Implications of BRAF-V600E mutation in Thyroid Neoplasm

  2025cites this paper
• Update on Somatic Genomic Alterations in Follicular Cell-Derived Thyroid Cancers.

  2025cites this paper
• Revisionist history uncovers a simplified molecular‐based classification of differentiated thyroid cancer

  2025cites this paper
• Homologous Recombination in Thyroid Tumor Samples

  2025cites this paper
• Molecular Pathology of Thyroid Follicular Epithelial Cell-Derived Neoplasia: An Update.

  2025cites this paper
• Accuracy comparison of direct Sanger sequencing, immunohistochemistry, and droplet digital polymerase chain reaction in detecting BRAF mutations in papillary thyroid carcinoma: a retrospective diagnostic accuracy study

  2025cites this paper
• A multi-omic analysis reveals a predictive value of tertiary lymphoid structures in improving the prognosis of colorectal cancer patients with BRAF mutation

  2025cites this paper
• Alteração na qualidade de vida de pacientes idosos submetidos a tireoidectomia total

  2024cites this paper
• Exploring the versatility of miRNA-128: a comprehensive review on its role as a biomarker and therapeutic target in clinical pathways

  2024cites this paper
• Clinically aggressive Follicular Cell-Derived Thyroid Carcinoma: A Comprehensive Series with Histomolecular Characterization and Discovery of Novel Gene Fusions.

  2024cites this paper
• Comparative efficiency of differential diagnostic methods for the identification of BRAF V600E gene mutation in papillary thyroid cancer (Review)

  2024cites this paper
• Papillary thyroid cancer and its gene polymorphism; A molecular mechanistic perspective

  2024cites this paper
• Thyroid Nodules: Past, Present & Future.

  2024cites this paper
• Polygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid Carcinoma.

  2024cites this paper
• Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN - ALK fusion.

  2024cites this paper
• An overview of RAF kinases and their inhibitors (2019-2023).

  2024cites this paper
• Association of polygenic score with tumor molecular subtypes in papillary thyroid carcinoma.

  2023cites this paper
• Genomic alterations in thyroid cancer: biological and clinical insights

  2023cites this paper
• Sacral metastases in a patient with BRAF V600E+ papillary thyroid carcinoma

  2023cites this paper
• TERT and BRAF V600E mutations in thyroid cancer of World Trade Center Responders.

  2023cites this paper
• Update on Molecular Diagnostics in Thyroid Pathology: A Review

  2023cites this paper
• Progress in Thyroid Cancer Genomics: A 40-Year Journey

  2023cites this paper
• Establishment of a BRAF V595E-mutant canine prostate cancer cell line and the antitumor effects of MEK inhibitors against canine prostate cancer.

  2023cites this paper
• The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy

  2023cites this paper
• Transcriptomic Analysis Reveals Dysregulation of the Mycobiome and Archaeome and Distinct Oncogenic Characteristics according to Subtype and Gender in Papillary Thyroid Carcinoma

  2023cites this paper
• Integrated metabolic and genetic analysis reveals distinct features of primary differentiated thyroid cancer and its metastatic potential in humans

  2023cites this paper
• Integrated metabolic and genetic analysis reveals distinct features of human differentiated thyroid cancer

  2023cites this paper
• Molecular diagnostics in the evaluation of thyroid nodules: Current use and prospective opportunities

  2023cites this paper
• BRAFV600E genetic testing should be recommended for Bethesda III or V thyroid nodules based on fine-needle aspiration

  2023cites this paper
• Molecular signature incorporating the immune microenvironment enhances thyroid cancer outcome prediction

  2023cites this paper
• Validation of dynamic risk stratification and impact of BRAF in risk assessment of thyroid cancer, a nation-wide multicenter study

  2023influential citation
• Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2

  2023cites this paper
• The Emerging Role of m6A Modification in Endocrine Cancer

  2023cites this paper
• Clinical use of molecular data in thyroid nodules and cancer.

  2023cites this paper
• Identification of BRAF, CCND1, and MYC mutations in a patient with multiple primary malignant tumors: a case report and review of the literature

  2023cites this paper
• Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules

  2023cites this paper
• How do BRAFV600E and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?

  2023cites this paper
• RET Fusion-Positive Papillary Thyroid Cancers are Associated with a More Aggressive Phenotype

  2022cites this paper
• Mutational analysis using next generation sequencing in pediatric thyroid cancer reveals BRAF and fusion oncogenes are common.

  2022cites this paper
• Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

  2022cites this paper
• Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)

  2022cites this paper
• Papillary Thyroid Cancer and a TERT Promotor Mutation-positive Paraganglioma in a Patient With a Germline SDHB Mutation

  2022cites this paper
• Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma

  2022cites this paper
• Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma

  2022cites this paper
• One hundred most‐cited articles in head and neck surgery and analysis of female authorship

  2022cites this paper
• BRAF gene mutation and papillary thyroid carcinoma

  2022cites this paper
• The combination of BRAFV600E mutation and Chinese Thyroid Imaging Reporting and Data System is helpful in the management of AUS/FLUS thyroid nodules

  2022cites this paper
• Molecular Testing for Thyroid Nodules: The Experience at McGill University Teaching Hospitals in Canada

  2022cites this paper
• A Perspective Study on the RTK, PI3K, B‐Raf, CDK and the Multi‐Protein Targeting in Medicinal Chemistry

  2022cites this paper
• Role of Tyrosine Kinase Receptors in Growth Factor Mediated Signal Transduction, with Specific Reference to MAPK/Rasand p13k-Akt Containing Pathways in Oncogenesis: A Qualitative Database Review

  2022cites this paper
• A New Indicator to Differentiate Thyroid Follicular Inclusions in Cervical Lymph Nodes from Patients with Thyroid Cancer

  2022cites this paper
• Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma

  2022cites this paper
• American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

  2022cites this paper
• 2022 Expert consensus on the use of laser ablation for papillary thyroid microcarcinoma

  2022cites this paper
• Comparison of the clinicopathological features and oncologic outcomes of the classic papillary thyroid carcinoma with tall cell features and tall cell variant.

  2021cites this paper
• Pediatric Surgical Pathology of the Thyroid and Parathyroid

  2021cites this paper
• Correlation between US-FNAC with BRAF V600E Mutation Analysis and Central Neck Lymph Node Metastasis in cN0 Papillary Thyroid Cancer

  2021cites this paper
• BRAFV600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

  2021cites this paper
• Development of a Molecular Assay for Detection and Quantification of the BRAF Variation in Residual Tissue From Thyroid Nodule Fine-Needle Aspiration Biopsy Specimens

  2021cites this paper
• 5 Molecular Characterization of Thyroid Neoplasia

  2021cites this paper
• Papillary Thyroid Cancer Prognosis: An Evolving Field

  2021cites this paper
• High Iodine Nutrition May Be a Risk Factor for Cervical Lymph Node Metastasis in Papillary Thyroid Cancer Patients

  2021cites this paper
• The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy

  2021cites this paper
• Multiparametric Photoacoustic Analysis of Human Thyroid Cancers In Vivo

  2021cites this paper
• Identifying Driver Genes Mutations with Clinical Significance in Thyroid Cancer

  2021cites this paper
• Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis

  2021cites this paper
• Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target

  2021cites this paper
• Integrated computational approaches on pyrazoline derivatives as B-Raf kinase inhibitors for the development of novel anticancer agents

  2021cites this paper
• Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors

  2021cites this paper
• Bisphenol A at a human exposed level can promote epithelial‐mesenchymal transition in papillary thyroid carcinoma harbouring BRAF V600E mutation

  2021cites this paper
• Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-RafV600E and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines.

  2021cites this paper
• Modern diagnostic technologies and molecular therapies in oncogenetics

  2021cites this paper
• Co‐existence of BRAF V600E‐mutated malignant melanoma and BRAF V600E‐mutated Langerhans cell histiocytosis: A case report

  2021cites this paper
• Upregulation of TRIB2 by Wnt/β-catenin activation in BRAFV600E papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib

  2021cites this paper
• Advances in Diagnosis and Treatment of Thyroid Cancer

  2020cites this paper
• Progress in Microbes and Molecular Biology

  2020cites this paper
• Analytical and clinical validation of pairwise microRNA expression analysis to identify medullary thyroid cancer in thyroid fine‐needle aspiration samples

  2020cites this paper
• Prediction of driver variants in the cancer genome via machine learning methodologies

  2020cites this paper
• Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs.

  2020cites this paper
• Mutations of the TERT promoter are associated with aggressiveness and recurrence/distant metastasis of papillary thyroid carcinoma.

  2020cites this paper
• Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non-small cell lung cancer patients: a multicenter retrospective study

  2020cites this paper
• Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer.

  2020cites this paper
• RASSF1A Methylation Status and BRAF V600E Immunohistochemical Expression in Odontogenic Lesions

  2020cites this paper
• The Role of BRAF Mutation (V600E) in Papillary Thyroid Carcinoma (PTC)

  2020cites this paper
• Molecular Markers in the Diagnosis of Thyroid Cancer in Indeterminate Thyroid Nodules

  2020cites this paper
• The Thyroid Tumor Microenvironment: Potential Targets for Therapeutic Intervention and Prognostication

  2020cites this paper
• Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay

  2020cites this paper
• Plasma miR-323 as a Biomarker for Screening Papillary Thyroid Cancer From Healthy Controls

  2020cites this paper
• The Role of BRAF Gene in Cancer: Literature Review and Future Directions

  2020cites this paper
• KRAS, BRAF, PIK3CA mutation frequency of radical prostatectomy samples and review of the literature

  2020cites this paper
• Indeterminate thyroid nodules in the era of molecular genomics

  2020cites this paper